Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

The Development of a Standardized Neighborhood Deprivation Index

Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

COVID-19 epidemiology

Ratnayake, A., McDougal, A. N., KISSINGER, P. J., Sokol, T. M., & Zheng, C. Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91812-1.00017-2 · Cited by 1

Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period

Sternberg, M., Johnson, A. G., King, J., Ali, A. R., Linde, L., Awofeso, A. O., Baker, J. S., Bayoumi, N. S., Broadway, S. E., Busen, K., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291678 · Cited by 2

Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration

Belda, F., Mora, O., López‐Martínez, M., Torres, N., Vivanco, A. B., Marfil, S., Pradenas, E., Massanella, M., Blanco, J., Christie, R., et al. (2023) · Plasmatology · doi:10.1177/26348535231202681 · Cited by 1

IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers

Rasheed, W. S., & Sarkees, A. N. (2023) · Medicine · doi:10.1097/md.0000000000035444 · Cited by 1

Vaccine effectiveness against the B.1.617.2 in the intensive care unit

Koc, I., Ozmen, S. U., & Deniz, O. (2023) · Medicine · doi:10.1097/md.0000000000035588 · Cited by 1

Evaluation of the Abdala Vaccine: Antibody and Cellular Response to the RBD Domain of SARS-CoV-2

Islas-Vázquez, L., Alvarado-Alvarado, Y. C., Cruz‐Aguilar, M., Velázquez-Soto, H., Villalobos-Gonzalez, E., Ornelas-Hall, G., Pérez‐Tapia, S. M., & Martínez, M. D. C. J. (2023) · Vaccines · doi:10.3390/vaccines11121787 · Cited by 2

Vaccine Effectiveness Against SARS-CoV-2 Related Hospitalizations in People who had Experienced Homelessness or Incarceration – Findings from the Minnesota EHR Consortium

DeSilva, M. B., Knowlton, G. S., Rai, N. K., Bodurtha, P. J., Essien, I. J., Riddles, J. J., Mehari, L., Muscoplat, M. H., Lynfield, R., Rowley, E. A. K., et al. (2023) · Journal of Community Health · doi:10.1007/s10900-023-01308-3 · Cited by 1

Development of inhaled COVID-19 vaccine and its benefits

Pu, Y. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3013000 · Cited by 1

Mathematical Optimization Strategy for Effectiveness Profile Estimation in Two-Dose Vaccines and Its Use in Designing Improved Vaccination Strategies Focused on Pandemic Containment

González-Sánchez, Ó. A., Zaldívar, D., Cuevas, E., & González-Ortiz, L. J. (2024) · Vaccines · doi:10.3390/vaccines12010081 · Cited by 1

Estimate Time-To-Infection (TTI) Vaccination Effect When TTI for Unvaccinated Group is Unknown

Chen, D., Chung, Y., & Beyene, K. M. (2024) · Statistics in Biosciences · doi:10.1007/s12561-024-09417-w · Cited by 1

Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients

Yoshifuji, A., Toda, M., Oyama, E., Nakayama, T., Mise‐Omata, S., Kikuchi, K., Yoshizawa, M., Kato, N., Wakai, H., Koibuchi, K., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02477-8 · Cited by 1

Efficacy, Effectiveness, and Safety of COVID-19 Vaccine Compared to Placebo in Preventing COVID-19 Infection among 12-17 Years Old: A Systematic Review

Gregorio, G. V., Catacutan, A. M. B., Perez, M. L. M., & Dans, L. F. (2024) · Acta Medica Philippina · doi:10.47895/amp.v58i7.7930 · Cited by 1

Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination

Younes, S. N., Nicolai, E., Pieri, M., Bernardini, S., Daas, H. I., Al‐Sadeq, D. W., Younes, N., Shurrab, F. M., Nizamuddin, P. B., Amanullah, F. H., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13290 · Cited by 3

Endolysosomal channel TMEM 175 mediates antitoxin activity of DABMA

Wu, Y., Huang, J., Zhang, F., Guivel‐Benhassine, F., Hubert, M., Schwartz, O., Xiao, W., Cintrat, J., Qu, L., Barbier, J., et al. (2024) · FEBS Journal · doi:10.1111/febs.17242 · Cited by 1

IMPACTO DA VACINAÇÃO CONTRA COVID-19 NOS DESFECHOS DE PACIENTES COM SÍNDROME RESPIRATÓRIA AGUDA GRAVE: UM ESTUDO DE COORTE RETROSPECTIVO NO DISTRITO FEDERAL (2020-2023)

Silva, L. C. M., Limeira, L. Q., Galhardo, L. M., da Silva, M. A. O., de Andrade, L. H. C., Martins, J. Z., dos Santos, L. L., MATTEI, M. B. Q., & Santos, P. H. P. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i8.5609 · Cited by 1

Effectiveness of COVID-19 Vaccination against Severe Symptoms and Death Among Geriatric Inpatients: A Retrospective Cohort Study in Macao

Zhang, X. Z., Wong, P. H. H., Lai, K. S., Yang, B., Song, M., Li, J., & Ung, C. O. L. (2024) · Vaccines · doi:10.3390/vaccines12080933 · Cited by 1

SARS-CoV-2 variant replacement constrains vaccine-specific viral diversification

Dearlove, B. L., Fries, A. C., Epsi, N. J., Richard, S. A., Ganesan, A., Huprikar, N., Lindholm, D. A., Mende, K., Colombo, R. E., Colombo, C. J., et al. (2024) · Virus Evolution · doi:10.1093/ve/veae071 · Cited by 1

Correlação espacial: padrão heterogêneo de mortalidade por covid-19 no Brasil

Moraes, A. I. D. S., Corrêa, A. P. D. V., Pereira, H. N. S., & Uehara, S. C. D. S. A. (2024) · Saúde em Debate · doi:10.1590/2358-289820241429255p · Cited by 1

Regarding “Risk of Cancers Proximal to the Colon in Fecal Immunochemical Test Positive Screenees in a Colorectal Cancer Screening Program”

Wu, J., Zhang, Z., & Zhang, L. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.09.046 · Cited by 1

Factors associated with COVID-19 in-hospital death and COVID-19 vaccine effectiveness against COVID-19 hospitalization in the Philippines during pre-omicron and omicron period: A case-control study (MOTIVATE-P study)

Arashiro, T., Solante, R., Sayo, A. R., Garcia, R. M., Kris, M., Suzuki, S., Malijan, G. M., Salazar, M. J., Salazar, M. A., Ortal-Cruz, A., et al. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824001845 · Cited by 1

Comparative Analysis of COVID‐19 Severity and Mortality Among Vaccinated and Unvaccinated Individuals During the Delta Variant Surge in a Tertiary Care Center: A Cohort Study

Hasani, F., Norouzi, Z., Jazi, K., Roshandel, G., & Norouzi, A. (2025) · Health Science Reports · doi:10.1002/hsr2.70346 · Cited by 1

SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography

Ma, J., Kaniper, S., Vabishchevich, Y., Nyantakyi, N., Lynch, D., Chun, F., Dai, H., & Gerhard, G. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-90730-9 · Cited by 1

Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331654 · Cited by 1

Fall 2021 Update

Schoonover-Shoffner, K. (2021) · Journal of Christian Nursing · doi:10.1097/cnj.0000000000000926 · Cited by 1

Epidemic on a changing network: College outbreaks and vaccination

Iyengar, M., Nimmagadda, V., & Khain, E. (2021) · International Journal of Modern Physics C · doi:10.1142/s0129183122500978 · Cited by 1

COVID-19 in the California Workers' Compensation System: A Study of COVID-19 Claims and Presumptions Under Senate Bill 1159

Quigley, D. D., Dworsky, M., Qureshi, N., Prier, S., & Gidengil, C. A. (2021) · RAND Corporation eBooks · doi:10.7249/rra1430-1 · Cited by 1

Mitigation strategies to safely conduct HIV treatment research in the context of COVID‐19

Henderson, M., Fidler, S. J., Mothe, B., Grinsztejn, B. G. J., Haire, B. G., Collins, S., Lau, J. S. Y., Luba, M., Sanne, I., Tatoud, R., et al. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25882 · Cited by 1

Omicron: A Ticking Time Bomb or a Blessing in Disguise? Leading towards a Deadly Wave or End of Pandemic?

Khandelwal, S. G., & Yau, Y. (2021) · LS International Journal of Life Sciences · doi:10.5958/2319-1198.2021.00020.8 · Cited by 1

新型コロナウイルスに対する治療・予防

Yoshifuji, A., & 竜崎, 崇. (2022) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.55.129 · Cited by 1

SARS-CoV-2-fertőzés és annak megelőzése gyermekkori krónikus szisztémás autoimmun betegségekben

Constantin, T., Kulcsár, A., Krivácsy, P., Mészner, Z., Ponyi, A., Tóth, A., Ónozó, B., & Szekanecz, Z. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32448 · Cited by 1

Research on improved SEIR model predicting UK Coronavirus variant Omicron outbreak

Ma, Z. (2022) · International Conference on Applied Mathematics, Modelling and Intelligent Computing (CAMMIC) · doi:10.1117/12.2638884 · Cited by 1

Using a Deep Neural Network in a Relative Risk Model to Estimate Vaccination Protection for COVID-19

Suchopárová, G., Vidnerová, P., Neruda, R., & Šmíd, M. (2022) · Communications in computer and information science · doi:10.1007/978-3-031-08223-8_26 · Cited by 1

Mandatory Vaccination: Analysis of the Application of the Practice of the European Court of Human Rights on Specific Bioethics

Кононенко, В. П. (2021) · Ukrainian Journal of International Law · doi:10.36952/uail.2021.4.61-69 · Cited by 1

Breath‐holding physiology, radiological severity and adverse outcomes in COVID ‐19 patients: A prospective validation study

Messineo, L., Fanfulla, F., Pedroni, L., Pini, F., Borghesi, A., Golemi, S., Vailati, G., Kerlin, K., Malhotra, A., Corda, L., et al. (2022) · Respirology · doi:10.1111/resp.14336 · Cited by 2

Estimate of undetected severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in acute-care hospital settings using an individual-based microsimulation model

Jones, K., Hadley, E., Preiss, S., Lofgren, E., Rice, D. P., Stoner, M. C. D., Rhea, S. K., & Adams, J. W. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.174 · Cited by 1

Real Life Evidence From the Use of COVID-19 mRNA Vaccines in Pediatric Populations

Lagousi, T., Tsagkli, P., & Spoulou, V. I. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003707 · Cited by 1

Clinical characteristics of patients hospitalized for COVID-19 vaccinated with at least two doses in a tertiary care hospital in Turkey

Toker, A. K., Özdemır, A. T., Yüksel, R. C., EREN, E. E., Toker, İ., & Çelik, İ. (2022) · Microbes Infection and Chemotherapy · doi:10.54034/mic.e1465 · Cited by 1

Indirect Virus Transmission via Fomites Can Counteract Lock-Down Effectiveness

Thalheim, T., Krüger, T., & Galle, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114011 · Cited by 1

Longitudinal Qualitative and Quantitative Evaluation of SARS-CoV-2 Antibodies in Immunized Health Care Workers

Hong, E., Nwabuo, C. C., King, A., Bocsi, G. T., Ashwood, E. R., & Harry, B. L. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0014-oa · Cited by 1

A study to assess the severity and risk of COVID-19 breakthrough infection in admitted SARS-CoV-2 vaccinated individual

Dhoble, S., Atram, D., Jiwane, N. N., & Naitam, A. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_485_23 · Cited by 1

Impact of non-pharmacological interventions on COVID-19 boosting vaccine prioritization and vaccine-induced herd immunity: a population-stratified modelling studyPreprint

Li, Z., Wang, J., Yang, B., Li, W., Xu, J., & Wang, T. (2021) · medRxiv · doi:10.1101/2021.10.27.21265522 · Cited by 1

Weak or No Correlation Between Recent COVID-19 Data and Vaccination Rates in FrancePreprint

Bouanane, M. (2021) · Research Square · doi:10.21203/rs.3.rs-1028704/v1 · Cited by 1

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021

(2021) · doi:10.1101/2021.11.12.21266222 · Cited by 1

Synergetic measures to contain highly transmissible variants of SARS-CoV-2Preprint

Su, H., Cheng, Y., Witt, C. C., Ma, N., & Pöschl, U. (2021) · medRxiv · doi:10.1101/2021.11.24.21266824 · Cited by 1

Individual vaccine efficacy variation with time since mRNA BNT162b2 vaccination estimated by rapid, quantitative antibody measurements from a finger-prick samplePreprint

Vargas, M. J. T., Chandrasekhar, M., Kwon, Y. J., Deijs, G. S., Corazza, C. M. O. W., Chai, A., Binedell, R. L., Jose, E., Govind, B., Huyet, L., et al. (2021) · medRxiv · doi:10.1101/2021.11.30.21267102 · Cited by 1

Temporal Changes in Factors Associated With COVID-19 Vaccine Hesitancy and Uptake Among Adults in Hong KongPreprint

Xiao, J., Cheung, J. K., Wu, P., Ni, M. Y., Cowling, B. J., & Liao, Q. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985388 · Cited by 1

Transmission of B.1.617.2 Delta Variant Between Vaccinated Healthcare WorkersPreprint

Kemp, S. A., Cheng, M. T. K., Hamilton, W., Kamelian, K., Singh, S. K., Rakshit, P., Aggrawal, A., Illing, C. J. R., & Gupta, R. K. (2022) · Research Square · doi:10.21203/rs.3.rs-1166169/v1 · Cited by 1

Waning of Vaccine-Conferred Protection against SARS-CoV-2 Infection: Matched Case-Control Test-Negative Design Study in Two High-Risk PopulationsPreprint

Goldhaber‐Fiebert, J. D., Prince, L., Chin, E. T., Leidner, D., Studdert, D. M., Salomon, J. A., & Andrews, J. R. (2022) · medRxiv · doi:10.1101/2022.01.21.22269664 · Cited by 1

Real-time monitoring of the effectiveness of six COVID-19 vaccines in Hungary in 2021 using the screening methodPreprint

Krisztina, H. J., Ferenci, T., Ferenczi, A., Túri, G., Röst, G., & Oroszi, B. (2022) · medRxiv · doi:10.1101/2022.02.18.22271179 · Cited by 1

Vaccine Effectiveness Against Hospitalization Among Adolescent and Pediatric SARS-CoV-2 Cases in Ontario, CanadaPreprint

Simmons, A. E., Amoako, A., Grima, A. A., Murison, K. R., Buchan, S. A., Tuite, A. R., & Fisman, D. N. (2022) · medRxiv · doi:10.1101/2022.03.24.22272919 · Cited by 1

Impact assessment of mobility restrictions, testing, and vaccination on the COVID-19 pandemic in IndiaPreprint

Shin, J., Long, K. Q., Abbas, K., & Oh, J. (2022) · medRxiv · doi:10.1101/2022.03.24.22272864 · Cited by 1

mRNA vaccine induces cytotoxic CD8+ T-cell cross-reactivity against SARS-CoV-2 Omicron variant and regulates COVID-19 severityPreprint

Nogimori, T., Suzuki, K., Masuta, Y., Yagoto, M., Ikeda, M., Katayama, Y., Washizaki, A., Kanda, H., Takada, M., Minami, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1364513/v1 · Cited by 1

Understanding differences in vaccination uptake among OECD countries

Turner, D., Woloszko, N., Chalaux, T., & Dek, M. (2022) · OECD Economics Department working papers · doi:10.1787/76482043-en · Cited by 3

Control Strategies for the Third wave of COVID-19 infection in India: A Mathematical Model Incorporating Vaccine EffectivenessPreprint

Mahajan, A., Sivadas, N., & Panda, P. (2022) · doi:10.36227/techrxiv.17705957.v1 · Cited by 1

A Deterministic Agent-based Model with Antibody Dynamics Information in COVID-19 Epidemic SimulationPreprint

Xu, Z., & Zhang, H. (2022) · medRxiv · doi:10.1101/2022.05.11.22274979 · Cited by 1

Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: test-negative case-control studyPreprint

Барчук, А. А., Bulina, A., Cherkashin, M., Berezina, N., Rakova, T., Kuplevatskaya, D., Skougarevskiy, D., & Okhotin, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1709300/v1 · Cited by 1

SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysisPreprint

Yamamoto, S., Matsuda, K., Maeda, K., Oshiro, Y., Inamura, N., Mizoue, T., Konishi, M., Takeuchi, J. S., Horii, K., Ozeki, M., et al. (2022) · medRxiv · doi:10.1101/2022.06.21.22276682 · Cited by 1

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysis

Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d’Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2022) · doi:10.1101/2022.07.04.22277225 · Cited by 1

Immunogenicity and Safety of Homologous and Heterologous Booster Vaccination of ChAdOx1 nCoV-19 (COVISHIELD TM) and BBV152 (COVAXIN®) in Previous Recipients of COVISHIELD TM or COVAXIN®: A Phase 4, Participant and Observer Blinded, Randomised StudyPreprint

Rose, W., Raju, R., Babji, S., George, A., Madhavan, R., Xavier, J. V. L., Chelladurai, J. S. D., Nikitha, O. S., Deborah, A. A., Vijayakumar, S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4143699 · Cited by 1

The Benefits and Costs of U.S. Employer COVID-19 Vaccine MandatesPreprint

Ferranna, M., Robinson, L. A., Cadarette, D., Eber, M., & Bloom, D. E. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4184326 · Cited by 1

The Benefits and Costs of U.S. Employer COVID-19 Vaccine MandatesPreprint

Ferranna, M., Robinson, L. A., Cadarette, D., Eber, M., & Bloom, D. E. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4188283 · Cited by 1

Low Antibody Titers Demonstrate Significantly Increased Rate of SARS-CoV-2 Infection in a Highly Vaccinated Population from the National Basketball AssociationPreprint

Tai, C. G.-L., Haviland, M. J., Kissler, S. M., Lucia, R. M., MERSON, M. H., Maragakis, L. L., Ho, D. D., Anderson, D. J., DiFiori, J. P., Grubaugh, N. D., et al. (2023) · medRxiv · doi:10.1101/2023.02.10.23285780 · Cited by 1

Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalisation using sentinel surveillance in South Africa, a test-negative case-control studyPreprint

Chiwandire, N., Walaza, S., von Gottberg, A., Wolter, N., du Plessis, M., Moosa, F., Groome, M. J., Nel, J. S., Variava, E., Dawood, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3423529/v1 · Cited by 1

Longitudinal Analysis of Neutralizing Antibodies Against SARS-CoV-1 and Different SARS-CoV-2 Strains in Breakthrough and Unvaccinated Covid-19 Patients in ThailandPreprint

Poolchanuan, P., Tiacharoen, V., Dulsuk, A., Phunpang, R., Runcharoen, C., Boonprakob, T., Hemtong, O., Chowplijit, S., Chuapaknam, V., Siripoon, T., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4871864 · Cited by 1

Health Surveillance and Epidemiological Profile of Severe Acute Respiratory Syndrome due to COVID-19 in Brazil (2020-2024)Preprint

Cândido-Sobrinho, S. A., Filho, J. Q. S., de Sousa, F., Viana, V. A. F., & Lima, A. Â. M. (2025) · medRxiv · doi:10.1101/2025.04.27.25326529 · Cited by 1

Non-linear Relationships between COVID-19 and Non-COVID-19 Mortality by Vaccination Status within Age GroupsPreprint

Oostenbrink, I. A. J. (2025) · medRxiv · doi:10.1101/2025.08.22.25333889 · Cited by 1

Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study of the UKPreprint

Xiang, Y., Feng, Y., Qiu, J., Zhang, R., & So, H. (2021) · medRxiv · doi:10.1101/2021.08.15.21262097

To Boost or Not to Boost (A Few More Takes)

Ellison, R. T. (2021) · Journal watch · doi:10.1056/nejm-jw.na54181

COVID 19 breakthrough infection risk: a simple physical model describing the dependence on antibody concentrationPreprint

Williams, D. E. (2021) · Research Square · doi:10.21203/rs.3.rs-1051588/v1

Der Herbst ist da und die dritte Impfung kommt

Weninger, W. (2021) · hautnah · doi:10.1007/s12326-021-00484-0

Population Optimally Immunized after Accounting for Type-Specific COVID-19 Vaccine Waning Intervals: State-Level Prevalence and TrendsPreprint

Pathak, E. B., & Salemi, J. L. (2021) · medRxiv · doi:10.1101/2021.12.09.21267295

A Novel CRISPR-Engineered, Stem Cell-Derived Cellular VaccinePreprint

Chakraborty, K., Chandrashekar, A., Sidaway, A., Latta, E., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., Mosher, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.28.474336

Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection from routine surveillance data in SwitzerlandPreprint

Anderegg, N., Althaus, C. L., Colin, S., Hauser, A., Laube, A., Mäusezahl, M., Wagner, M. G., Zaffora, B., & Riou, J. (2021) · doi:10.31219/osf.io/rxk9b

COVID 19 breakthrough infection risk: a simple physical model describing the dependence on antibody concentrationPreprint

Williams, D. E. (2021) · Research Square · doi:10.21203/rs.3.rs-1051588/v2

Faut-il vacciner les enfants contre la COVID-19 ?

(2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.12.010

Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy

Homan, T., Fortunato, F., Corso, G., Lopalco, P. L., Prato, R., & Martinelli, D. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00582-9

Våre kollegaer står uvaksinerte i frontlinjen

Dahl, E. H., & Tveter, I. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0810 · Cited by 1

COVID‐19 Vaccine Efficacy and the Evidence on BoostersPreprint

Black, B. S., & Thaw, D. B. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3987991

SUSTAINED BENEFICIAL EFFECTS OF VACCINATION ON THE CASE FATALITY RATE FOR COVID-19 INFECTIONSPreprint

Murata, G. H., Murata, A. E., Perkins, D. J., Campbell, H. M., Mao, J. T., Wagner, B., McMahon, B. H., & Hagedorn, C. H. (2022) · medRxiv · doi:10.1101/2022.01.22.22269689

‘Anatomy of SARS-CoV-2 outbreak of ‘vaccinated’: An observational case-control study of COVID-19 breakthrough infections, COVID-19 appropriate behavior and anti-spike-IgG response as a correlate of protection in Medical college students at Rural Medical College, IndiaPreprint

Chavan, M. N., Gayatri, S., Patil, S. N., Deshpande, J., Yadav, A., Nakate, P., Shelke, Y. P., & Nillawar, A. (2022) · medRxiv · doi:10.1101/2022.01.27.22269902

Additional Doses of Vaccines against COVID-19 - Attempting to Enhance the Immune Response

Alvez, F. (2022) · doi:10.36959/669/748

Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort studyPreprint

Molani, S., Baumgartner, A. M., Hwang, Y. M., Duvvuri, V. R. S. K., Goldman, J. D., & Hadlock, J. (2022) · medRxiv · doi:10.1101/2022.02.07.22270613

Pasaporte COVID, ¿sí o no?

Batalla, C. (2022) · Atención Primaria Práctica · doi:10.1016/j.appr.2022.100128

Trajectory of SARS-CoV-2 anti-S IgG levels following transfusion and a third dose of BNT162b2 vaccine in a patient with massive postoperative bleeding: A case report

Hirata, M., Fukuchi, T., & Sugawara, H. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.042

We are on time

Lucas, J. H., Soriano, C., López-Olivencia, M., & Ortíz, A. B. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100411

Effekt av tre doser koronavaksine

Vaksdal, H. H., & Grødeland, G. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0096

Development of vaccines against COVID-19

古澤, 夢., 山吉, 誠., & 河岡, 義. (2022) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.59.16

The clinical characteristics of 541 fully vaccinated hospitalized COVID-19 patients in a Tertiary Care Hospital in TurkeyPreprint

Toker, A. K., Özdemır, A. T., Yüksel, R. C., EREN, E. E., Çelik, İ., & Toker, İ. (2022) · Research Square · doi:10.21203/rs.3.rs-1531157/v1

COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donorsPreprint

Grebe, E., Yu, E. A., Bravo, M. D., Welte, A., Bruhn, R. L., Stone, M., Green, V., Williamson, P. C., Feldstein, L. R., Jones, J. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1551694/v1

Vanishing and spreading conditions for a free-boundary epidemic model with subclinical infections and vaccination

Chen, F., Chen, S., & Yang, W. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022307

COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donorsPreprint

Grebe, E., Yu, E. A., Bravo, M. D., Welte, A., Bruhn, R. L., Stone, M., Green, V., Williamson, P. C., Feldstein, L. R., Jones, J. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1551694/v2

Control Strategies for the Third wave of COVID-19 infection in India: A Mathematical Model Incorporating Vaccine EffectivenessPreprint

Mahajan, A., Sivadas, N., & Panda, P. (2022) · doi:10.36227/techrxiv.17705957

Accuracy of COVID-19-Like-Illness Diagnoses in Electronic Health Record Data (Preprint)Preprint

Rao, S., Bozio, C. H., Butterfield, K. A., Reynolds, S. B., Reese, S. E., Ball, S. W., Steffens, A., Demarco, M., McEvoy, C., Thompson, M. G., et al. (2022) · doi:10.2196/preprints.39231

Exploring Motivations for COVID-19 Vaccination among Black Young Adults in Three Southern States (Preprint)Preprint

Stoner, M. C. D., Browne, E. N., Tweedy, D., Pettifor, A. E., Maragh‐Bass, A. C., Toval, C., Tolley, E. E., Comello, M. L. G., Muessig, K. E., Henna Budhwani, P., et al. (2022) · doi:10.2196/preprints.39144

Comparative epidemiology of ivermectin and vaccines against Delta variant based on real-world data and hypothesized mechanisms of ivermectin immunological actionPreprint

Tanioka, H., Tanioka, S., & Kaga, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1631602/v1

Should vaccinated people be prioritized for COVID-19 care? Reply to Ramphul.

Vergallo, G. M., Varone, M. C., & RIO, A. D. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i2.12412

Risk of SARS-CoV2 by vaccination status and population characteristics in Qatar

Syed, M. A., Nuaimi, A. S. A., & Qotba, H. A. A. (2022) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2022.100148

Disease profile and patient outcomes in vaccinated COVID-19 patients at a tertiary care Indian hospital: An observational, real-world study

Chopra, M., Gupta, A., Shafin Babu, P. S., Kapoor, R., Sirohi, Y. S., & Nilakantan, A. (2022) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2022.04.004

Clinical and virologic factors associated with outcomes of COVID‐19 before and after vaccination among Veterans: Retrospective analysis from six New England states

Lee, M. L., Cosentino, D., Kyriakides, T. C., Cavallaro, T., Stack, G. E., & Gupta, S. (2022) · Journal of Hospital Medicine · doi:10.1002/jhm.12852

Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?

Takeuchi, M., Esaki, A., Higa, Y., & Nakazono, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263486

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort StudyPreprint

Tartof, S. Y., Slezak, J. M., Fischer, H. J., Hong, V. X., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3909743 · Cited by 30

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant

Risk, M., Shen, C., Hayek, S. S., Holevinski, L., Schiopu, E., Freed, G. L., Akin, C., & Zhao, L. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac106 · Cited by 28

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative DesignPreprint

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Alegiani, S. S., Filia, A., D’Ancona, F. “., Manso, M. D., Riccardo, F., Tallon, M., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069052 · Cited by 111